RCS - Abingdon Health PLC - Launch of LVOne Stroke Test by UpFront Diagnostics

Abingdon HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260511:nRSK6837Da&default-theme=true

RNS Number : 6837D  Abingdon Health PLC  11 May 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

UK Launch of LVOne Stroke Triage Test by UpFront Diagnostics

 

York, UK and Madison, WI, USA, 11 May 2026: Abingdon Health plc (AIM: ABDX)
(OTCQB: ABDXF), a leading international developer, manufacturer and regulatory
services provider for rapid diagnostic tests and med-tech, notes the
announcement on 5 May 2026
(https://upfrontdiagnostics.com/blog/lvone-launches-in-uk-after-ukca-approval/)
by its customer, UpFront Diagnostics, regarding the UK commercial launch of
LVOne, the world's first rapid blood test for identifying a stroke at the
point of care, following UKCA marking and the commencement of a deployment in
partnership with London Ambulance Service ("LAS").

 

LVOne is designed to help paramedics identify patients likely to be
experiencing a large vessel occlusion ("LVO") stroke in the pre-hospital
setting. The test measures two blood biomarkers: D-dimer, associated with clot
formation, and GFAP, associated with bleeding in the brain, to help
differentiate stroke types and identify likely LVO patients, with results
delivered in under 10 minutes from a finger-prick blood sample. Earlier
identification of LVO enables paramedics to alert hospitals that a LVO patient
is coming and allow them to prioritise time-critical treatment.  An estimated
1.9 million brain cells are lost every minute following stroke onset.

 

Abingdon Health's role

Abingdon Health has acted as CDMO partner to Upfront Diagnostics for LVOne,
delivering feasibility through scale-up, quality control, robustness testing,
validation, and routine manufacture of the test's two assays. The programme
navigated a number of technical challenges, including evolving project scope
during technical transfer, inter-dependent dual-biomarker development, and
complex reagent lead times. The successful UKCA marking and commercial launch
of LVOne is a strong illustration of how the Company's CDMO capability, aids
development through to deployment of a customer's lateral flow product.

 

The deployment

The initial deployment by UpFront Diagnostics will equip approximately 280 LAS
vehicles serving North Central London, before expanding to North West and
North East London, covering a population of approximately 6.5 million people,
during a six-month pilot. The London programme is being led by Dr Robert
Simister, consultant neurologist at the National Hospital for Neurology and
Neurosurgery, University College London Hospitals (UCLH), in collaboration
with LAS and several major stroke centres across the capital.

 

 

Gonzalo Ladreda, CEO and co-founder of UpFront Diagnostics, commented:

"Abingdon Health's expertise has been instrumental in bringing our stroke
detection lateral flow test closer to reality."

 

Chris Yates, Chief Commercial Officer of Abingdon Health, commented:

"We are delighted to see LVOne reach UK patients following UKCA marking and to
have supported UpFront Diagnostics as their CDMO partner and manufacturer on
this important programme. LVOne is a powerful illustration of how lateral flow
technology can be applied to time-critical clinical decision making in
pre-hospital emergency care.

 

"Stroke is one of the leading causes of death and long-term disability in the
UK, and the ability to identify likely LVO strokes within minutes, in the
ambulance, has the potential to deliver meaningful improvements in patient
outcomes. We congratulate the team at UpFront Diagnostics, London Ambulance
Service and the clinical leadership at UCLH on this milestone, and we look
forward to supporting UpFront Diagnostics as the programme progresses."

 

Any shareholders wishing to keep up to date with Abingdon Health news, please
email abingdon@walbrookpr.com

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                                         Via Walbrook PR
 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                    Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/lateral-flow-cdmo-development)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, regulatory strategy support, technology transfer and manufacturing services
(https://www.abingdonhealth.com/services/lateral-flow-scale-up-technical-transfer)
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format.  Abingdon Health has the
internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, including companion diagnostics
(https://www.abingdonhealth.com/services/companion-diagnostics-ivd-cdmo) ,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services
(https://www.abingdonhealth.com/services/regulatory-services/) companies,
Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of
regulatory services to the in vitro diagnostic and wider medical device
industry, to support customers in bringing products to market across a range
of territories including the USA, EU and the UK. Its consultancy services
range from design, implementation and maintenance of quality management
systems, preparation of technical files for regulatory approvals, part-time
and interim management support, auditing both internal and external,
management reviews and presentations, training and mentoring.  The Company's
subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance
evaluation
(https://www.abingdonhealth.com/services/performance-evaluation-services/) to
generate the required technical and data for regulatory approval for lateral
flow and other in vitro diagnostic assays from its Doncaster, England
facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochures
(https://www.abingdonhealth.com/knowledge-centre/brochures-guides)  outlines
the comprehensive support the Group can now provide to its international
customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

LEI - 213800XFI4WV3FBILO20

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEANSPEAPKEFA



            Copyright 2019 Regulatory News Service, all rights reserved